The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech.
June 18, 2026 09:40 AM EDTUpdated 04:34 PM
FinancingStartups
RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
Kyle LaHucik
Biotech Correspondent
[Bio USA] Korean biotechs bolster AstraZeneca partnership
AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman…
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's…
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for…
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
